RxDoctor Payments Data

Asha Byrd

Physician Assistant · Roseville, CANPI 1568035756

Payments from drug & device makers

$3,494in general payments, 2019–2025

Across 154 payments — averaging $22.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$707
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$613
  • Scilex Pharmaceuticals Inc.$407
  • Abbott$362
  • Collegium Pharmaceutical, Inc.$243
  • Forte Bio-pharma LLC$189
  • plus $972 from 20 others

What the payments were for

  • Food & beverage$3,494100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,494 in reported general payments places this provider in the 85th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$122,185
Medicare patients
279
Services billed
1,101

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZtlidoLidocaine77$51,895
RelistorMethylnaltrexone Bromide20$43,244
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen756$25,575
BelbucaBuprenorphine Hcl35$21,392
OxycontinOxycodone Hcl45$17,581
Xtampza ErOxycodone Myristate24$13,815
MovantikNaloxegol Oxalate27$10,788
Lidocaine104$9,299
Buprenorphine31$9,118
Diclofenac Sodium127$7,853
SymproicNaldemedine Tosylate16$7,754
Hysingla ErHydrocodone Bitartrate12$5,598
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen132$5,132
Celecoxib33$4,977
Morphine Sulfate ErMorphine Sulfate163$3,993

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Scilex Pharmaceuticals Inc.Ztlido$407$51,89577 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$613$43,24420 claims
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$243$35,20659 claims
Redhill Biopharma Inc.Movantik$45$10,78827 claims
Hikma Pharmaceuticals USABuprenorphine, Buprenorphine Hcl$40$9,84742 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Roseville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →